+
Lupin To Present Cancer Drug Data at ASCO 2025
ECONOMY & POLICY

Lupin To Present Cancer Drug Data at ASCO 2025

Global pharmaceutical firm Lupin Limited will present results from its Phase 1a clinical trial of LNP7457—a novel PRMT5 inhibitor—at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago from 30 May to 3 June 2025. The data will be showcased during the Developmental Therapeutics—Molecularly Targeted Agents and Tumour Biology session on 2 June, between 1:30 pm and 4:30 pm (CDT), at Poster Board #422.

LNP7457 is a SAM-competitive PRMT5 inhibitor being developed for monotherapy in patients with advanced or metastatic solid tumours. According to trial findings, the drug has shown a favourable safety and tolerability profile, with pharmacokinetic/pharmacodynamic (PK/PD) data supporting further development. Food intake was found to have no impact on drug metabolism.

The maximum tolerated dose and the recommended Phase 2 dose were established based on cumulative safety, PK/PD, and efficacy data, and are consistent with preclinical models and existing safety profiles of PRMT5 inhibitors.

Vinita Gupta, CEO of Lupin, commented, “We are pleased to share encouraging data from our Phase I trial. LNP7457 represents a novel epigenetic therapeutic with significant promise, and reinforces our commitment to advancing innovative treatments for cancers with limited options.”

Lupin has already commenced its Phase 1b trial in India and aims to further evaluate LNP7457 for various oncology indications where unmet clinical needs persist.

Presentation Details:
4. Date: 2 June 2025
5. Time: 1:30–4:30 pm CDT
6. Location: Hall A, McCormick Place, Chicago
7. Abstract No.: 3107 | Poster Board No.: 422
8. Trial Registration: CTRI/2023/07/054753
9. DOI: 10.1200/JCO.2025.43.16_suppl.3107

Lupin’s participation at ASCO underscores its focus on precision oncology and its ambitions in the field of targeted cancer therapies.

Global pharmaceutical firm Lupin Limited will present results from its Phase 1a clinical trial of LNP7457—a novel PRMT5 inhibitor—at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago from 30 May to 3 June 2025. The data will be showcased during the Developmental Therapeutics—Molecularly Targeted Agents and Tumour Biology session on 2 June, between 1:30 pm and 4:30 pm (CDT), at Poster Board #422.LNP7457 is a SAM-competitive PRMT5 inhibitor being developed for monotherapy in patients with advanced or metastatic solid tumours. According to trial findings, the drug has shown a favourable safety and tolerability profile, with pharmacokinetic/pharmacodynamic (PK/PD) data supporting further development. Food intake was found to have no impact on drug metabolism.The maximum tolerated dose and the recommended Phase 2 dose were established based on cumulative safety, PK/PD, and efficacy data, and are consistent with preclinical models and existing safety profiles of PRMT5 inhibitors.Vinita Gupta, CEO of Lupin, commented, “We are pleased to share encouraging data from our Phase I trial. LNP7457 represents a novel epigenetic therapeutic with significant promise, and reinforces our commitment to advancing innovative treatments for cancers with limited options.”Lupin has already commenced its Phase 1b trial in India and aims to further evaluate LNP7457 for various oncology indications where unmet clinical needs persist.Presentation Details:4. Date: 2 June 20255. Time: 1:30–4:30 pm CDT6. Location: Hall A, McCormick Place, Chicago7. Abstract No.: 3107 | Poster Board No.: 4228. Trial Registration: CTRI/2023/07/0547539. DOI: 10.1200/JCO.2025.43.16_suppl.3107Lupin’s participation at ASCO underscores its focus on precision oncology and its ambitions in the field of targeted cancer therapies.

Next Story
Real Estate

Manglam, Fern Hotels Sign 200+ Key Apart’otel in Jaipur’s Pinkwalk

Manglam Group has signed a 200+ key serviced apart’otel under the Fern Habitat brand in Jaipur, marking a key milestone in its Rs 10 billion hospitality investment strategy. Located within Pinkwalk, Manglam’s flagship mixed-use development in Jagatpura, the project will cater to both short and extended-stay travellers with apartment-style units paired with hotel services. The Fern Habitat Pinkwalk will offer fully serviced accommodations with kitchenettes, daily housekeeping, and on-site dining. The concept blends the independence of apartment living with the comfort of hotel-grade am..

Next Story
Real Estate

Schon Doorways Launches Monsoon-Ready Aluminium Casement Windows

Schon Doorways, a premium player in doors and window solutions, has launched its new range of aluminium casement and sliding windows, designed specifically to endure the Indian monsoon. Engineered with high-performance tempered glass and ultra-slim aluminium profiles, the windows combine aesthetic appeal with monsoon resilience. Available in single and double track options, the windows offer anti-collision strips, flyscreens, and high load-bearing strength—providing protection against heavy rains, strong winds, and pests. Wall thickness ranges from 1.6 mm to 5.00 mm, offering flexibilit..

Next Story
Resources

LG Charts Global HVAC Leadership With AI, Acquisitions and Localisation

LG Electronics has unveiled a strategic roadmap to transform its ES Company into a top-tier global HVAC solutions provider by 2030, targeting KRW 20 trillion in revenue. The plan, announced at LG Sciencepark, South Korea, focuses on expanding B2B industrial sales, advancing AI-based technologies for data centres, and strengthening localised operations across key regions. Central to LG’s roadmap is growth in the fast-expanding data centre cooling segment. With the global chiller market projected to reach USD 12 billion by 2027, LG aims for KRW 1 trillion in sales by 2027. The company has..

Advertisement

Advertisement

Subscribe to Our Newsletter

Get daily newsletters around different themes from Construction world.

STAY CONNECTED

Advertisement

Advertisement

Advertisement

Advertisement

Talk to us?